Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03964480 · ClinicalTrials.gov registry record
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
A clinical trial of Peripheral T-Cell Lymphoma, sponsored by Associazione Angela Serra per la ricerca sul cancro.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 6
- Study locations
NCT03964480 is a study of Peripheral T-Cell Lymphoma that is actively recruiting participants, run by Associazione Angela Serra per la ricerca sul cancro. The registered enrollment target is 1,000 participants, above the 77-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (1199% higher). The trial reports 6 study locations across 2 states.
The verdict
NCT03964480, a study of Peripheral T-Cell Lymphoma, is actively recruiting participants, sponsored by Associazione Angela Serra per la ricerca sul cancro.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to verify whether this prospective collection of data would allow achieving a more accurate information on T-cell lymphomas. The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population as well as molecular markers and to explore the prognostic or predictive implications of them in PTCL. The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population.
Conditions Studied
Study Locations (6)
Other
- IRCCS Istituto Tumori "Giovanni Paolo II" - Bari
- Palermo_La Maddalena - Palermo
- Terni-Santa Maria - Terni
- Cluj Napoca_Ion Chiricuta Oncology Institute - Cluj-Napoca
- National Cancer Institute - Kiev
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2018-10-14 |
| Est. Completion | 2025-07-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03964480
The ClinicalTrials.gov registry entry for NCT03964480 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 77-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (1199% higher). The listed sponsor is Associazione Angela Serra per la ricerca sul cancro, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT03964480 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT03964480 about?
NCT03964480 is a clinical study titled "Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.". This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the pr...
What is the current status of trial NCT03964480?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2018-10-14. Estimated completion is 2025-07-30.
What conditions does trial NCT03964480 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma.
Who is sponsoring clinical trial NCT03964480?
This trial is sponsored by Associazione Angela Serra per la ricerca sul cancro, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03964480 being conducted?
This trial has 6 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RECRUITING · Phase 1
-
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
RECRUITING · Early Phase 1
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.